Malarone (Proguanil Hydrochloride, Atovaquone)

Malarone is an antimalarial used for malaria chemoprophylaxis and treatment of acute infections.

• Malaria prophylaxis: prevents infection in travelers and residents of endemic regions.
• Uncomplicated P. falciparum malaria treatment: clears parasites and resolves symptoms.
• Uncomplicated malaria caused by other Plasmodium species: provides effective parasite clearance.

• Atovaquone inhibits the mitochondrial electron transport chain (cytochrome bc1 complex) of Plasmodium parasites, disrupting ATP synthesis, while proguanil is metabolized to cycloguanil, which blocks dihydrofolate reductase, impairing nucleic acid synthesis. The combined action results in synergistic parasite killing.

Malarone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial pain.
• Abdominal pain: discomfort in the stomach area.
• Diarrhea: loose stools.
• Vomiting: expulsion of stomach contents.
• Metallic taste: altered taste perception.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hemolysis in G6PD deficiency: rapid destruction of red blood cells.
• Anaphylaxis: life‑threatening allergic response.
• Neutropenia: marked reduction in white blood cells.

Before prescribing Malarone, clinicians should consider several safety measures.

• Renal or hepatic assessment: evaluate function before initiating therapy.
• Hypersensitivity: avoid in patients with known allergy to atovaquone or proguanil.
• Pregnancy and lactation: use only if benefit outweighs risk, as safety data are limited.
• Monitoring: watch for signs of severe skin reactions or hepatic dysfunction during treatment.
• Drug interactions: review concomitant medications that may affect absorption or metabolism.
• Store at below 25°C: keep in the original pack, protect from moisture.

Malarone can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Rifampin: induces metabolism, markedly lowering atovaquone and proguanil plasma levels.
• Antacids containing aluminum or magnesium: decrease atovaquone absorption when taken together.
• Certain antiretrovirals (e.g., zidovudine): may increase toxicity risk.

Moderate Interactions (Monitor Closely)

• CYP2C8 inhibitors (e.g., amiodarone): may raise atovaquone concentrations.
• CYP3A4 inhibitors (e.g., ketoconazole): can increase proguanil levels.
• Warfarin: may require INR monitoring due to potential interaction.